Frontotemporal Lobar Degeneration TDP-43-Immunoreactive Pathological Subtypes: Clinical and Mechanistic Significance
Open accessThe DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
Frontotemporal lobar degeneration with TPD-43-immunoreactive pathology (FTLD-TDP) is subclassified based on the type and cortical laminar distribution of neuronal inclusions. The relevance of these pathological subtypes is supported by the presence of relatively specific clinical and genetic correlations. Recent evidence suggests that the different patterns of pathology are a reflection of biochemical differences in the pathological TDP-43 species, each of which is influenced by differing genetic factors. As a result, patient FTLD-TDP subtype may be an important factor to consider when developing biomarkers and targeted therapies for frontotemporal dementia. In this review, we first describe the pathological features, clinical and genetic correlations of the currently recognized FTLD-TDP subtypes. We then discuss a number of novel patterns of TDP-43 pathology. Finally, we provide an overview of what is currently known about the biochemical basis of the different FTLD-TDP subtypes and how this may explain the observed phenotypic and pathological heterogeneity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Arai, T., Hasegawa, M., Akiyama, H., Ikeda, K., Nonaka, T., Mori, H., Mann, D., Tsuchiya, K., Yoshida, M., Hashizume, Y., et al. (2006) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2006.10.093 · Cited by 2,732
Limbic-predominant age-related TDP-43 encephalopathy (LATE): consensus working group report
Nelson, P. T., Dickson, D. W., Trojanowski, J. Q., Jack, C. R., Boyle, P. A., Arfanakis, K., Rademakers, R., Alafuzoff, I., Attems, J., Brayne, C., et al. (2019) · Brain · doi:10.1093/brain/awz099 · Cited by 1,547
Mackenzie, I. R. A., Neumann, M., Bigio, E. H., Cairns, N. J., Alafuzoff, I., Kril, J., Kovacs, G. G., Ghetti, B., Halliday, G., Holm, I. E., et al. (2010) · Acta Neuropathologica · doi:10.1007/s00401-009-0612-2 · Cited by 1,012
Self-citationPhosphorylated TDP‐43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis
Hasegawa, M., Arai, T., Nonaka, T., Kametani, F., Yoshida, M., Hashizume, Y., Beach, T. G., Buratti, E., Baralle, F., Morita, M., et al. (2008) · Annals of Neurology · doi:10.1002/ana.21425 · Cited by 777
Snowden, J. S., Rollinson, S., Thompson, J. C., Harris, J. M., Stopford, C. L., Richardson, A. M. T., Jones, M., Gerhard, A., Davidson, Y. S., Robinson, A., et al. (2012) · Brain · doi:10.1093/brain/awr355 · Cited by 523
Staging TDP-43 pathology in Alzheimer’s disease
Josephs, K. A., Murray, M. E., Whitwell, J. L., Parisi, J. E., Petrucelli, L., Jack, C. R., Petersen, R. C., & Dickson, D. W. (2014) · Acta Neuropathologica · doi:10.1007/s00401-013-1211-9 · Cited by 366
Clinicopathological correlations in behavioural variant frontotemporal dementia
Perry, D. C., Brown, J. A., Possin, K. L., Datta, S., Trujillo, A., Radke, A., Karydas, A., Kornak, J., Sias, A. C., Rabinovici, G. D., et al. (2017) · Brain · doi:10.1093/brain/awx254 · Cited by 309
Porta, S., Xu, Y., Restrepo, C. R., Kwong, L. K., Zhang, B., Brown, H. J., Lee, E. B., Trojanowski, J. Q., & Lee, V. M.-Y. (2018) · Nature Communications · doi:10.1038/s41467-018-06548-9 · Cited by 248
Self-citationBrady, O. A., Meng, P., Zheng, Y., Mao, Y., & Hu, F. (2011) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2010.07098.x · Cited by 215
Loss of TBK1 is a frequent cause of frontotemporal dementia in a Belgian cohort
Gijselinck, I., Van Mossevelde, S., van der Zee, J., Sieben, A., Philtjens, S., Heeman, B., Engelborghs, S., Vandenbulcke, M., De Baets, G., Bäumer, V., et al. (2015) · Neurology · doi:10.1212/wnl.0000000000002220 · Cited by 174
Genetics of FTLD : overview and what else we can expect from genetic studies
Pottier, C., Ravenscroft, T. A., Sanchez‐Contreras, M., & Rademakers, R. (2016) · Journal of Neurochemistry · doi:10.1111/jnc.13622 · Cited by 148
Research works printed but not linked: 78
- Woollacott IO, Rohrer JD (2016) The clinical spectrum of sporadic and familial forms of frontotemporal dementia. J Neurochem 138(Suppl 1):6–31 · DOI · Paper page
- Mackenzie IR, Neumann M, Bigio EH, Cairns NJ, Alafuzoff I, Kril J et al (2009) Nomenclature for neuropathologic subtypes of frontotemporal lobar degeneration: consensus recommendations. Acta Neuropathol 117(1):15–18 · DOI · Paper page
- Mackenzie IR, Shi J, Shaw CL, Duplessis D, Neary D, Snowden JS et al (2006) Dementia lacking distinctive histology (DLDH) revisited. Acta Neuropathol 112(5):551–559 · DOI
- Mackenzie IR, Baborie A, Pickering-Brown S, Du Plessis D, Jaros E, Perry RH et al (2006) Heterogeneity of ubiquitin pathology in frontotemporal lobar degeneration: classification and relation to clinical phenotype. Acta Neuropathol 112(5):539–549 · DOI · Paper page
- Sampathu DM, Neumann M, Kwong LK, Chou TT, Micsenyi M, Truax A et al (2006) Pathological heterogeneity of frontotemporal lobar degeneration with ubiquitin-positive inclusions delineated by ubiquitin immunohistochemistry and novel monoclonal antibodies. Am J Pathol 169(4):1343–1352 · DOI · Paper page
- Forman MS, Mackenzie IR, Cairns NJ, Swanson E, Boyer PJ, Drachman DA et al (2006) Novel ubiquitin neuropathology in frontotemporal dementia with valosin-containing protein gene mutations. J Neuropathol Exp Neurol 65(6):571–581 · DOI · Paper page
- Holm IE, Englund E, Mackenzie IR, Johannsen P, Isaacs AM (2007) A reassessment of the neuropathology of frontotemporal dementia linked to chromosome 3. J Neuropathol Exp Neurol 66(10):884–891 · DOI · Paper page
- Mackenzie IR, Baker M, Pickering-Brown S, Hsiung GY, Lindholm C, Dwosh E et al (2006) The neuropathology of frontotemporal lobar degeneration caused by mutations in the progranulin gene. Brain 129(Pt 11):3081–3090 · DOI · Paper page
- Neumann M, Sampathu DM, Kwong LK, Truax AC, Micsenyi MC, Chou TT et al (2006) Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science 314(5796):130–133 · DOI · Paper page
- Cairns NJ, Neumann M, Bigio EH, Holm IE, Troost D, Hatanpaa KJ et al (2007) TDP-43 in familial and sporadic frontotemporal lobar degeneration with ubiquitin inclusions. Am J Pathol 171(1):227–240 · DOI · Paper page
- Davidson Y, Kelley T, Mackenzie IR, Pickering-Brown S, Du Plessis D, Neary D et al (2007) Ubiquitinated pathological lesions in frontotemporal lobar degeneration contain the TAR DNA-binding protein, TDP-43. Acta Neuropathol 113(5):521–533 · DOI · Paper page
- Mackenzie IR, Neumann M (2017) Reappraisal of TDP-43 pathology in FTLD-U subtypes. Acta Neuropathol 134(1):79–96 · DOI
- Laferriere F, Maniecka Z, Perez-Berlanga M, Hruska-Plochan M, Gilhespy L, Hock EM et al (2019) TDP-43 extracted from frontotemporal lobar degeneration subject brains displays distinct aggregate assemblies and neurotoxic effects reflecting disease progression rates. Nat Neurosci 22(1):65–77 · DOI · Paper page
- Pottier C, Ren Y, Perkerson RB 3rd, Baker M, Jenkins GD, van Blitterswijk M et al (2019) Genome-wide analyses as part of the international FTLD-TDP whole-genome sequencing consortium reveals novel disease risk factors and increases support for immune dysfunction in FTLD. Acta Neuropathol 137(6):879–899 · DOI · Paper page
- Tsuji H, Arai T, Kametani F, Nonaka T, Yamashita M, Suzukake M et al (2012) Molecular analysis and biochemical classification of TDP-43 proteinopathy. Brain 135(Pt 11):3380–3391 · DOI · Paper page
- Neumann M, Kwong LK, Lee EB, Kremmer E, Flatley A, Xu Y et al (2009) Phosphorylation of S409/410 of TDP-43 is a consistent feature in all sporadic and familial forms of TDP-43 proteinopathies. Acta Neuropathol 117(2):137–149 · DOI · Paper page
- Mackenzie IR, Neumann M, Baborie A, Sampathu DM, Du Plessis D, Jaros E et al (2011) A harmonized classification system for FTLD-TDP pathology. Acta Neuropathol 122(1):111–113 · DOI · Paper page
- Josephs KA, Stroh A, Dugger B, Dickson DW (2009) Evaluation of subcortical pathology and clinical correlations in FTLD-U subtypes. Acta Neuropathol 118(3):349–358 · DOI · Paper page
- Mackenzie IR, Neumann M (2020) Subcortical TDP-43 pathology patterns validate cortical FTLD-TDP subtypes and demonstrate unique aspects of C9orf72 mutation cases. Acta Neuropathol 139(1):83–98 · DOI
- Josephs KA, Hodges JR, Snowden JS, Mackenzie IR, Neumann M, Mann DM et al (2011) Neuropathological background of phenotypical variability in frontotemporal dementia. Acta Neuropathol 122(2):137–153 · DOI · Paper page
- Rohrer JD, Lashley T, Holton J, Revesz T, Urwin H, Isaacs AM et al (2011) The clinical and neuroanatomical phenotype of FUS associated frontotemporal lobar degeneration. J Neurol Neurosurg Psychiatry 82(12):1405–1407 · DOI · Paper page
- Al-Obeidi E, Al-Tahan S, Surampalli A, Goyal N, Wang AK, Hermann A et al (2018) Genotype-phenotype study in patients with valosin-containing protein mutations associated with multisystem proteinopathy. Clin Genet 93(1):119–125 · DOI · Paper page
- Neumann M, Mackenzie IR, Cairns NJ, Boyer PJ, Markesbery WR, Smith CD et al (2007) TDP-43 in the ubiquitin pathology of frontotemporal dementia with VCP gene mutations. J Neuropathol Exp Neurol 66(2):152–157 · DOI · Paper page
- Bigio EH, Weintraub S, Rademakers R, Baker M, Ahmadian SS, Rademaker A et al (2013) Frontotemporal lobar degeneration with TDP-43 proteinopathy and chromosome 9p repeat expansion in C9ORF72: clinicopathologic correlation. Neuropathology 33(2):122–133 · DOI
- Boeve BF, Boylan KB, Graff-Radford NR, DeJesus-Hernandez M, Knopman DS, Pedraza O et al (2012) Characterization of frontotemporal dementia and/or amyotrophic lateral sclerosis associated with the GGGGCC repeat expansion in C9ORF72. Brain 135(Pt 3):765–783 · DOI · Paper page
- Mahoney CJ, Beck J, Rohrer JD, Lashley T, Mok K, Shakespeare T et al (2012) Frontotemporal dementia with the C9ORF72 hexanucleotide repeat expansion: clinical, neuroanatomical and neuropathological features. Brain 135(Pt 3):736–750 · DOI · Paper page
- Murray ME, Dejesus-Hernandez M, Rutherford NJ, Baker M, Duara R, Graff-Radford NR et al (2011) Clinical and neuropathologic heterogeneity of c9FTD/ALS associated with hexanucleotide repeat expansion in C9ORF72. Acta Neuropathol 122(6):673–690 · DOI · Paper page
- Hirsch-Reinshagen V, Alfaify OA, Hsiung GR, Pottier C, Baker M, Perkerson RB 3rd et al (2019) Clinicopathologic correlations in a family with a TBK1 mutation presenting as primary progressive aphasia and primary lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener 20:568–575 · DOI
- Koriath CA, Bocchetta M, Brotherhood E, Woollacott IO, Norsworthy P, Simon-Sanchez J et al (2017) The clinical, neuroanatomical, and neuropathologic phenotype of TBK1-associated frontotemporal dementia: a longitudinal case report. Alzheimers Dement (Amst) 6:75–81 · DOI · Paper page
- Lamb R, Rohrer JD, Real R, Lubbe SJ, Waite AJ, Blake DJ et al (2019) A novel TBK1 mutation in a family with diverse frontotemporal dementia spectrum disorders. Cold Spring Harb Mol Case Stud 5(3):a003913 · DOI
- Alafuzoff I, Pikkarainen M, Neumann M, Arzberger T, Al-Sarraj S, Bodi I et al (2015) Neuropathological assessments of the pathology in frontotemporal lobar degeneration with TDP43-positive inclusions: an inter-laboratory study by the BrainNet Europe consortium. J Neural Transm 122(7):957–972 · DOI
- Pikkarainen M, Hartikainen P, Alafuzoff I (2008) Neuropathologic features of frontotemporal lobar degeneration with ubiquitin-positive inclusions visualized with ubiquitin-binding protein p62 immunohistochemistry. J Neuropathol Exp Neurol 67(4):280–298 · DOI · Paper page
- Shinagawa S, Naasan G, Karydas AM, Coppola G, Pribadi M, Seeley WW et al (2015) Clinicopathological study of patients with C9ORF72-associated frontotemporal dementia presenting with delusions. J Geriatr Psychiatry Neurol 28(2):99–107 · DOI · Paper page
- Lee EB, Porta S, Michael Baer G, Xu Y, Suh E, Kwong LK et al (2017) Expansion of the classification of FTLD-TDP: distinct pathology associated with rapidly progressive frontotemporal degeneration. Acta Neuropathol 134(1):65–78 · DOI · Paper page
- Takeuchi R, Tada M, Shiga A, Toyoshima Y, Konno T, Sato T et al (2016) Heterogeneity of cerebral TDP-43 pathology in sporadic amyotrophic lateral sclerosis: evidence for clinico-pathologic subtypes. Acta Neuropathol Commun 4(1):61 · DOI
- Tan RH, Guennewig B, Dobson-Stone C, Kwok JBJ, Kril JJ, Kiernan MC et al (2019) The underacknowledged PPA-ALS: a unique clinicopathologic subtype with strong heritability. Neurology 92(12):e1354–e1e66 · DOI
- Armstrong RA, Ellis W, Hamilton RL, Mackenzie IR, Hedreen J, Gearing M et al (2010) Neuropathological heterogeneity in frontotemporal lobar degeneration with TDP-43 proteinopathy: a quantitative study of 94 cases using principal components analysis. J Neural Transm (Vienna) 117(2):227–239 · DOI · Paper page
- Nishihira Y, Gefen T, Mao Q, Appin C, Kohler M, Walker J et al (2019) Revisiting the utility of TDP-43 immunoreactive (TDP-43-ir) pathology to classify FTLD-TDP subtypes. Acta Neuropathol 138(1):167–169 · DOI
- Clark CN, Quaegebeur A, Nirmalananthan N, MacKinnon AD, Revesz T, Holton JL et al (2019) Foix-Chavany-Marie syndrome due to type E TDP43 pathology. Neuropathol Appl Neurobio l46(3):292–295. · DOI
- Ihori N, Araki S, Ishihara K, Kawamura M (2006) A case of frontotemporal lobar degeneration with progressive dysarthria. Behav Neurol 17(2):97–104 · DOI
- Lee EB, Lee VM, Trojanowski JQ, Neumann M (2008) TDP-43 immunoreactivity in anoxic, ischemic and neoplastic lesions of the central nervous system. Acta Neuropathol 115(3):305–311 · DOI
- Brenner M, Johnson AB, Boespflug-Tanguy O, Rodriguez D, Goldman JE, Messing A (2001) Mutations in GFAP, encoding glial fibrillary acidic protein, are associated with Alexander disease. Nat Genet 27(1):117–120 · DOI · Paper page
- Walker AK, Daniels CM, Goldman JE, Trojanowski JQ, Lee VM, Messing A (2014) Astrocytic TDP-43 pathology in Alexander disease. J Neurosci 34(19):6448–6458 · DOI · Paper page
- Farrer MJ, Hulihan MM, Kachergus JM, Dachsel JC, Stoessl AJ, Grantier LL et al (2009) DCTN1 mutations in Perry syndrome. Nat Genet 41(2):163–165 · DOI · Paper page
- Mishima T, Koga S, Lin WL, Kasanuki K, Castanedes-Casey M, Wszolek ZK et al (2017) Perry syndrome: a distinctive type of TDP-43 Proteinopathy. J Neuropathol Exp Neurol 76(8):676–682 · DOI
- Josephs KA, Mackenzie I, Frosch MP, Bigio EH, Neumann M, Arai T et al (2019) LATE to the PART-y. Brain 142(9):e47 · DOI · Paper page
- Buratti E (2018) TDP-43 post-translational modifications in health and disease. Expert Opin Ther Targets 22(3):279–293 · DOI · Paper page
- Igaz LM, Kwong LK, Xu Y, Truax AC, Uryu K, Neumann M et al (2008) Enrichment of C-terminal fragments in TAR DNA-binding protein-43 cytoplasmic inclusions in brain but not in spinal cord of frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Am J Pathol 173(1):182–194 · DOI · Paper page
- Igaz LM, Kwong LK, Chen-Plotkin A, Winton MJ, Unger TL, Xu Y et al (2009) Expression of TDP-43 C-terminal fragments in vitro recapitulates pathological features of TDP-43 Proteinopathies. J Biol Chem 284(13):8516–8524 · DOI · Paper page
- Nonaka T, Kametani F, Arai T, Akiyama H, Hasegawa M (2009) Truncation and pathogenic mutations facilitate the formation of intracellular aggregates of TDP-43. Hum Mol Genet 18(18):3353–3364 · DOI · Paper page
- Zhang YJ, Xu YF, Dickey CA, Buratti E, Baralle F, Bailey R et al (2007) Progranulin mediates caspase-dependent cleavage of TAR DNA binding protein-43. J Neurosci 27(39):10530–10534 · DOI · Paper page
- Dormann D, Capell A, Carlson AM, Shankaran SS, Rodde R, Neumann M et al (2009) Proteolytic processing of TAR DNA binding protein-43 by caspases produces C-terminal fragments with disease defining properties independent of progranulin. J Neurochem 110(3):1082–1094 · DOI · Paper page
- Herskowitz JH, Gozal YM, Duong DM, Dammer EB, Gearing M, Ye K et al (2012) Asparaginyl endopeptidase cleaves TDP-43 in brain. Proteomics 12(15–16):2455–2463 · DOI · Paper page
- Yamashita T, Hideyama T, Hachiga K, Teramoto S, Takano J, Iwata N et al (2012) A role for calpain-dependent cleavage of TDP-43 in amyotrophic lateral sclerosis pathology. Nat Commun 3:1307 · DOI · Paper page
- Xiao S, Sanelli T, Chiang H, Sun Y, Chakrabartty A, Keith J et al (2015) Low molecular weight species of TDP-43 generated by abnormal splicing form inclusions in amyotrophic lateral sclerosis and result in motor neuron death. Acta Neuropathol 130(1):49–61 · DOI
- Nishimoto Y, Ito D, Yagi T, Nihei Y, Tsunoda Y, Suzuki N (2010) Characterization of alternative isoforms and inclusion body of the TAR DNA-binding protein-43. J Biol Chem 285(1):608–619 · DOI · Paper page
- Zhang YJ, Xu YF, Cook C, Gendron TF, Roettges P, Link CD et al (2009) Aberrant cleavage of TDP-43 enhances aggregation and cellular toxicity. Proc Natl Acad Sci U S A 106(18):7607–7612 · DOI · Paper page
- Berning BA, Walker AK (2019) The pathobiology of TDP-43 C-terminal fragments in ALS and FTLD. Front Neurosci 13:335 · DOI · Paper page
- Josephs KA, Zhang YJ, Baker M, Rademakers R, Petrucelli L, Dickson DW (2019) C-terminal and full length TDP-43 specie differ according to FTLD-TDP lesion type but not genetic mutation. Acta Neuropathol Commun 7(1):100 · DOI
- Kametani F, Nonaka T, Suzuki T, Arai T, Dohmae N, Akiyama H et al (2009) Identification of casein kinase-1 phosphorylation sites on TDP-43. Biochem Biophys Res Commun 382(2):405–409 · DOI
- Inukai Y, Nonaka T, Arai T, Yoshida M, Hashizume Y, Beach TG et al (2008) Abnormal phosphorylation of Ser409/410 of TDP-43 in FTLD-U and ALS. FEBS Lett 582(19):2899–2904 · DOI · Paper page
- Tan RH, Shepherd CE, Kril JJ, McCann H, McGeachie A, McGinley C et al (2013) Classification of FTLD-TDP cases into pathological subtypes using antibodies against phosphorylated and non-phosphorylated TDP43. Acta Neuropathol Commun 1:33 · DOI · Paper page
- Kim KY, Lee HW, Shim YM, Mook-Jung I, Jeon GS, Sung JJ (2015) A phosphomimetic mutant TDP-43 (S409/410E) induces Drosha instability and cytotoxicity in neuro 2A cells. Biochem Biophys Res Commun 464(1):236–243 · DOI
- Li HY, Yeh PA, Chiu HC, Tang CY, Tu BP (2011) Hyperphosphorylation as a defense mechanism to reduce TDP-43 aggregation. PLoS One 6(8):e23075 · DOI · Paper page
- Seyfried NT, Gozal YM, Dammer EB, Xia Q, Duong DM, Cheng D et al (2010) Multiplex SILAC analysis of a cellular TDP-43 proteinopathy model reveals protein inclusions associated with SUMOylation and diverse polyubiquitin chains. Mol Cell Proteomics 9(4):705–718 · DOI · Paper page
- Dammer EB, Fallini C, Gozal YM, Duong DM, Rossoll W, Xu P et al (2012) Coaggregation of RNA-binding proteins in a model of TDP-43 proteinopathy with selective RGG motif methylation and a role for RRM1 ubiquitination. PLoS One 7(6):e38658 · DOI · Paper page
- Hans F, Eckert M, von Zweydorf F, Gloeckner CJ, Kahle PJ (2018) Identification and characterization of ubiquitinylation sites in TAR DNA-binding protein of 43 kDa (TDP-43). J Biol Chem 293(41):16083–16099 · DOI · Paper page
- Kim W, Bennett EJ, Huttlin EL, Guo A, Li J, Possemato A et al (2011) Systematic and quantitative assessment of the ubiquitin-modified proteome. Mol Cell 44(2):325–340 · DOI · Paper page
- Wagner SA, Beli P, Weinert BT, Nielsen ML, Cox J, Mann M et al (2011) A proteome-wide, quantitative survey of in vivo ubiquitylation sites reveals widespread regulatory roles. Mol Cell Proteomics 10(10):M111 013284 · DOI · Paper page
- Kametani F, Obi T, Shishido T, Akatsu H, Murayama S, Saito Y et al (2016) Mass spectrometric analysis of accumulated TDP-43 in amyotrophic lateral sclerosis brains. Sci Rep 6:23281 · DOI · Paper page
- Cohen TJ, Hwang AW, Restrepo CR, Yuan CX, Trojanowski JQ, Lee VM (2015) An acetylation switch controls TDP-43 function and aggregation propensity. Nat Commun 6:5845 · DOI · Paper page
- Cohen TJ, Hwang AW, Unger T, Trojanowski JQ, Lee VM (2012) Redox signalling directly regulates TDP-43 via cysteine oxidation and disulphide cross-linking. EMBO J 31(5):1241–1252 · DOI · Paper page
- Aguzzi A, Heikenwalder M, Polymenidou M (2007) Insights into prion strains and neurotoxicity. Nat Rev Mol Cell Biol 8(7):552–561 · DOI · Paper page
- Kawakami I, Arai T, Hasegawa M (2019) The basis of clinicopathological heterogeneity in TDP-43 proteinopathy. Acta Neuropathol 138(5):751–770 · DOI · Paper page
- Hasegawa M, Nonaka T, Tsuji H, Tamaoka A, Yamashita M, Kametani F et al (2011) Molecular dissection of TDP-43 proteinopathies. J Mol Neurosci 45(3):480–485 · DOI
- Nonaka T, Masuda-Suzukake M, Arai T, Hasegawa Y, Akatsu H, Obi T et al (2013) Prion-like properties of pathological TDP-43 aggregates from diseased brains. Cell Rep 4(1):124–134 · DOI · Paper page
- Davidson YS, Robinson AC, Flood L, Rollinson S, Benson BC, Asi YT et al (2017) Heterogeneous ribonuclear protein E2 (hnRNP E2) is associated with TDP-43-immunoreactive neurites in semantic dementia but not with other TDP-43 pathological subtypes of frontotemporal lobar degeneration. Acta Neuropathol Commun 5(1):54 · DOI
- Kattuah W, Rogelj B, King A, Shaw CE, Hortobagyi T, Troakes C (2019) Heterogeneous nuclear ribonucleoprotein E2 (hnRNP E2) is a component of TDP-43 aggregates specifically in the a and C pathological subtypes of frontotemporal lobar degeneration. Front Neurosci 13:551 · DOI
Cited by
Frontotemporal lobar degeneration
Grossman, M., Seeley, W. W., Boxer, A. L., Hillis, A. E., Knopman, D. S., Ljubenov, P. A., Miller, B., Piguet, O., Rademakers, R., Whitwell, J. L., et al. (2023) · Nature Reviews Disease Primers · doi:10.1038/s41572-023-00447-0 · Cited by 178
Advances in treatment of frontotemporal dementia
Magrath Guimet, N., Zapata-Restrepo, L. M., & Miller, B. L. (2022) · The Journal of Neuropsychiatry and Clinical Neurosciences · doi:10.1176/appi.neuropsych.21060166 · Cited by 52
Elevated nuclear TDP-43 induces constitutive exon skipping
Carmen-Orozco, R. P., Tsao, W., Ye, Y., Sinha, I. R., Chang, K., Trinh, V. T., Chung, W., Bowden, K., Troncoso, J. C., Blackshaw, S., et al. (2024) · Molecular Neurodegeneration · doi:10.1186/s13024-024-00732-w · Cited by 27
Barnard, L., Botha, H., Corriveau-Lecavalier, N., Graff-Radford, J., Dicks, E., Gogineni, V., Zhang, G., Burkett, B. J., Johnson, D. R., Huls, S. J., et al. (2025) · Neurology · doi:10.1212/wnl.0000000000213831 · Cited by 25
Ohm, D. T., Rhodes, E., Bahena, A., Capp, N., Lowe, M., Sabatini, P., Trotman, W., Olm, C. A., Phillips, J., Prabhakaran, K., et al. (2023) · Frontiers in Neurology · doi:10.3389/fneur.2023.1245886 · Cited by 6
Self-citation
Metadata
- Authors
- Neumann, M., Lee, E. B., & Mackenzie, I. R.
- Venue
- Advances in Experimental Medicine and Biology
- Publisher
- Springer International Publishing
- Published
- 2021
- Volume
- 1281
- Pages
- 201-217
- ISSN
- 0065-2598 (ISSN-L)
- 2214-8019
- OpenAlex
- W3118777027
- Cited by
- 103
- References
- 11
- FWCI
- 64.89
- Type
- book chapter
- Language
- en
- Open access
- green
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.